PORTAGE, Mich., Feb. 9, 2026 /PRNewswire/ -- Stryker (NYSE: SYK), a global leader in medical technologies, announced the limited market release of Mako RPS (Robotic Power System) for Total Knee, an intuitive handheld robotic system that combines Stryker's proven robotics and power tool legacies and represents Mako's expansion into a new robotics platform. Mako now includes Mako SmartRobotics™ – Stryker's multi-specialty, robotic-arm assisted platform featuring Mako 4 – and Mako Handheld Robotics with Mako R ...

以下文章来源于AI医疗观察 ，作者关注AI医疗的 AI医疗观察 . 响应《关于深入实施"人工智能+"行动的意见》，推动AI在医疗领域的应用，本账号发布权威资讯 在手术室的角落里，一个 AI引擎正以每秒千次的速度，审阅着全球数万份临床报告，将美敦力一款新心脏起搏器的上市时间悄悄提前了半年；在 GE医疗的全球仓库中，无形的算法网络正实时调度着数万种零部件，悄然锁定了数亿美元本会闲置的现金。 这些没有发布会、不产生炫目 DEMO的"静默革命"，正在成为2026年全球医疗科技领域真正的资本主线。摩根士丹利、贝恩等顶级机构在开年密 集发出报告，核心指向一个颠覆性趋势：聪明的钱，正急速从追逐"AI医疗初创公司"的喧嚣中撤离，转而重仓那些正在用AI系统性改造自己、且 已看到惊人效率提升的传统医疗巨头——美敦力、直觉外科、GE医疗、波士顿科学。 一场由 "效率"定义的静默革命，正在成为2026年全球医疗科技领域真正的资本主线。其核心信号是： 聪明的钱，正急速从追逐 "纯AI工具"的喧 嚣中撤离，转而重仓那些正在用AI系统性改造自己、并能清晰证明效率提升的传统医疗巨头。 行业领袖们并非在产品上简单添加 AI模块，而是正在沿三条 ...

Austin, United States, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Surgical Staplers Market Size & Growth Analysis: According to SNS Insider, The Surgical Staplers Market was valued at USD 6.41 billion in 2025 and is projected to reach USD 10.87 billion by 2033, growing at a CAGR of 6.87% during the forecast period 2026-2033. The global burden of chronic diseases that require surgical intervention, rising surgical procedure volumes, and the growing acceptance of minimally invasive and laparoscopic surgeries are all f ...

Stryker Corporation (NYSE:SYK) is one of the 12 best Medical Devices stocks to invest in according to Hedge Funds. On January 27, Matthew O’Brien from Piper Sandler reiterated his Overweight rating on Stryker Corporation (NYSE:SYK) with a price target of $420. His target price estimate represents over 17% upside for investors. O’Brien shed light on the company’s new handheld orthopedic robot, identified as Mako RPS, after connecting with a physician who had seen the product. According to the initial stu ...

Stryker Corporation (SYK) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $4.47, which beat the Zacks Consensus Estimate of $4.40 by 1.6%. The bottom line also improved 11.5% year over year. Our model estimate for the metric was pegged at $3.15 per share.GAAP EPS was $2.22, up 2.8% from the year-ago quarter’s level.For the full year, adjusted EPS gained 11.8% to $13.63. GAAP EPS was $8.40, up 8.2% from the year-ago level.Revenue DetailsRevenues totaled $7.17 billion, which beat the Zacks C ...

Core Insights - Stryker reported revenue of $7.17 billion for the quarter ended December 2025, reflecting an 11.4% increase year-over-year and surpassing the Zacks Consensus Estimate of $7.13 billion by 0.61% [1] - The company's EPS was $4.47, up from $4.01 in the same quarter last year, exceeding the consensus estimate of $4.40 by 1.71% [1] Financial Performance - International net sales reached $1.73 billion, slightly above the average estimate of $1.72 billion, marking a year-over-year increase of 10.7% [4] - U.S. net sales were reported at $5.44 billion, matching the average estimate and showing an 11.7% increase year-over-year [4] - MedSurg and Neurotechnology sales totaled $4.56 billion, exceeding the estimated $4.53 billion, with a significant year-over-year growth of 17.5% [4] Segment Analysis - Orthopaedics sales amounted to $2.61 billion, aligning with estimates and reflecting a 2.2% year-over-year increase [4] - Within Orthopaedics, hips sales were $499 million, slightly below the estimated $504.79 million, but still showing a 7.8% increase year-over-year [4] - Trauma and Extremities sales were $1.09 billion, below the estimated $1.1 billion, with a year-over-year growth of 9% [4] Key Metrics - Stryker's stock has returned 1.8% over the past month, outperforming the Zacks S&P 500 composite's 0.8% change [3] - The company holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market [3]

Group 1 - The core viewpoint is that Stryker, a medical equipment maker, has raised its full-year profit forecast due to strong sales of its implants and other medical devices [1] Group 2 - The company is experiencing robust demand for its products, which is contributing to the positive outlook for the year [1] - The increase in profit forecast indicates confidence in the company's growth trajectory within the medical device industry [1]

Stryker (NYSE:SYK) Q4 2025 Earnings call January 29, 2026 04:30 PM ET Company ParticipantsDavid Roman - Managing DirectorJason Beach - VP of Finance and Head of Investor RelationsJoanne Wuensch - Managing DirectorKevin Lobo - Chair and CEOPatrick Wood - Managing DirectorPreston Wells - CFORichard Newitter - Managing DirectorConference Call ParticipantsCaitlin Roberts - AnalystChris Pasquale - AnalystDanielle Antalffy - AnalystDrew Ranieri - AnalystJeff Johnson - AnalystLarry Biegelsen - Senior AnalystMatt M ...

Stryker (NYSE:SYK) Q4 2025 Earnings call January 29, 2026 04:30 PM ET Company ParticipantsDavid Roman - Managing DirectorJason Beach - VP of Finance and Head of Investor RelationsJoanne Wuensch - Managing DirectorKevin Lobo - Chair and CEOPatrick Wood - Managing DirectorPreston Wells - CFORichard Newitter - Managing DirectorConference Call ParticipantsCaitlin Roberts - AnalystChris Pasquale - Senior Analyst for Medical Devices & SuppliesDanielle Antalffy - AnalystDrew Ranieri - AnalystJeff Johnson - Analyst ...

Stryker (NYSE:SYK) Q4 2025 Earnings call January 29, 2026 04:30 PM ET Speaker2Welcome to the fourth quarter and full year 2025 Stryker Earnings Call. My name is Layla, and I'll be your operator for today's call. At this time, all participants are in a listen-only mode. Following the conference, we will conduct a question-and-answer session. This conference call is being recorded for replay purposes. Before we begin, I would like to remind you that the discussions during this conference call will include for ...